Phase II Study of Bryostatin 1 in Patients with Relapsed Multiple Myeloma (original) (raw)
Abstract
Bryostatin 1, a macrocyclic lactoneisolated from the marine bryozoan Bugula neritina,is a protein kinase C (PKC) modulator which has shown bothpreclinical and clinical activity inlymphoid malignancies. We conducted aphase II trial of bryostatin 1 administeredat a dose of 120 μg/m2 by 72-hcontinuous infusion every 2 weeks inpatients with relapsed multiple myeloma. Treatment was well tolerated with myalgiasconstituting the primaray toxicity. Therewere no responses in nine evaluablepatients. The preclinical anti-lymphoidactivity is strong enough to supportfurther exploration of bryostatin 1 indifferent schedules and in combinationtherapy for multiple myeloma.
Access this article
Subscribe and save
- Get 10 units per month
- Download Article/Chapter or eBook
- 1 Unit = 1 Article or 1 Chapter
- Cancel anytime Subscribe now
Buy Now
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
Instant access to the full article PDF.
Similar content being viewed by others
References
- Pettit GR, Herald SL, Doubek DL: Isolation and structure of bryostatin 1. J Am Chem Soc 104: 6846–6848, 1982
Google Scholar - Kraft AS, Smith JB, Berkow RL: Bryostatin, an activator of calcium phospholipid-dependent protein kinase, blocks phorbol ester-induced differentiation of human promyelocytic HL-60 cells. Proc Natl Acad Sci USA 83: 1334–1338, 1986
Google Scholar - National Cancer Institute: Guidelines for Reporting of Adverse Drug Reactions. Bethesda, MD, Division of Cancer Treatment, National Cancer Institute, 1988
Google Scholar - Mohammad RM, Al-Katib A, Pettit GR, Sensenbrenner LL: Successful treatment of human Waldenstrom's macroglobulinemia with combination biological and chemotherapy agents. Cancer Res 54: 165–168, 1994
Google Scholar - Mohammad RM, Diwakaran H, Maii A, Emara MA, Pettit GR, Redman B, Al-Katib A: Bryostatin 1 induces apoptosis and augments inhibitory effects of vincristine in human diffuse large cell lymphoma. Leuk Res 19: 667–673, 1995
Google Scholar - Al-Katib A, Smith MR, Kamanda WS, Pettit GR, Hamdan M, Mohamed AN, Chelladurai B, Mohammad RM: Bryostatin 1 down-regulates mdr1 and potentitates vincristine cytotoxicity in diffuse large cell lymphoma xenografts. Clin Cancer Res 4: 1305–1314, 1998
Google Scholar - Maki A, Diwakaran H, Redman B, Al-Asfar, S, Pettit GR, Mohammad RM, Al-Katib A: The bcl-2 and p53 oncoproteins can be modulated by bryostatin 1 and dolastatins in human diffuse large cell lymphoma. Anticancer Drugs 6: 392–397, 1995
Google Scholar - Varterasian ML, Mohammad RM, Eilender DS, Hulburd K, Rodriguez D, Pemberton PA, Pluda J, Dan MD, Pettit GR, Chen B, Al-Katib: Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia. J Clin Oncol 16: 56–62, 1998
Google Scholar - Varterasian ML, Mohammad RM, Shurafa MS, Hulburd K, Pamberton PA, Rodriguez DH, Spadoni V, Eilender DS, Murgo A, Wall N, Dan M, Al-Katib AM: Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Clin Cancer Res 6: 825–828, 2000
Google Scholar
Author information
Authors and Affiliations
- Karmanos Cancer Institute, Wayne State University, Detroit, MI, U.S.A.
Mary L. Varterasian, Pamela A. Pemberton, Kim Hulburd, Dorothy H. Rodriguez & Ayad M. Al-Katib - Investigational Drug Branch, CTEP, DCTDC, NCI, Rockville, MD, U.S.A.
Anthony Murgo
Authors
- Mary L. Varterasian
You can also search for this author inPubMed Google Scholar - Pamela A. Pemberton
You can also search for this author inPubMed Google Scholar - Kim Hulburd
You can also search for this author inPubMed Google Scholar - Dorothy H. Rodriguez
You can also search for this author inPubMed Google Scholar - Anthony Murgo
You can also search for this author inPubMed Google Scholar - Ayad M. Al-Katib
You can also search for this author inPubMed Google Scholar
Rights and permissions
About this article
Cite this article
Varterasian, M.L., Pemberton, P.A., Hulburd, K. et al. Phase II Study of Bryostatin 1 in Patients with Relapsed Multiple Myeloma.Invest New Drugs 19, 245–247 (2001). https://doi.org/10.1023/A:1010676719178
- Issue Date: August 2001
- DOI: https://doi.org/10.1023/A:1010676719178